About Tesamorelin

Mechanism of Action: Tesamorelin is a synthetic, stabilized 44–amino-acid analogue of human growth-hormone–releasing hormone (GHRH) that binds to GHRH receptors on pituitary somatotrophs, stimulating endogenous pulsatile secretion of growth hormone (GH). This leads to downstream increases in insulin-like growth factor 1 (IGF-I) and activation of metabolic pathways that promote lipolysis and reduce visceral adipose tissue (VAT).

Indications & Off-Label Uses: Tesamorelin (Egrifta®/Egrifta SV®) is FDA-approved for the reduction of excess abdominal (visceral) fat in HIV-infected patients with lipodystrophy. Off-label, it has been explored in non-HIV populations for visceral fat reduction, metabolic improvement, cognitive enhancement, and anti-aging purposes, though these uses remain investigational. Preliminary studies in older adults and non-HIV populations demonstrate reductions in VAT and triglycerides, modest improvements in lipid profiles, and potential neuroprotective effects, but evidence remains limited and long-term efficacy outside HIV-associated lipodystrophy is unproven.

FDA Status & Availability: Tesamorelin is an FDA-approved, commercially manufactured prescription drug marketed as Egrifta SV®.  It remains the only GHRH analogue currently approved by the FDA for a specific clinical indication.

Safety & Monitoring: Common adverse effects include injection-site erythema or pruritus, arthralgia, peripheral edema, myalgia, and paresthesia. Tesamorelin can increase IGF-I and GH levels, potentially affecting glucose metabolism with glucose intolerance and new-onset diabetes reported. Caution is warranted in patients with active malignancy, history of pituitary disease, or those at risk for glucose dysregulation. Periodic monitoring of IGF-I, fasting glucose/HbA1c, and lipid profile is recommended during therapy. Long-term safety is limited.